Direct oral anticoagulants for treatment of deep vein thrombosis: Overview of systematic reviews
Carregando...
Data
2018-10-01
Autores
Brandão, Gustavo Muçouçah Sampaio
Cândido, Raissa Carolina Fonseca
Rollo, Hamilton de Almeida [UNESP]
Sobreira, Marcone Lima [UNESP]
Junqueira, Daniela R.
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
A number of limitations of standard therapy with warfarin for deep vein thrombosis (DVT) have been established. This overview of systematic reviews presents the baseline results for efficacy and safety of the new direct oral anticoagulants (DOACs) thrombin inhibitors, and activated factor X (Xa) inhibitors in patients with DVT. Searches were run on PubMed and the Cochrane Database of Systematic Reviews. Twenty-three studies were retrieved, and one systematic review was judged eligible. This review scored maximum according to AMSTAR criteria and included 7,596 patients for analysis of thrombin inhibitors and 16,356 patients for analysis of factor Xa inhibitors. The results of the meta-analysis indicate that DOACs are similar for DVT treatment when compared to standard treatment with warfarin. The incidence of major bleeding is somewhat lower in patients treated with factor Xa inhibitors and similar to standard therapy when treated with direct thrombin inhibitors.
Descrição
Palavras-chave
Deep venous thrombosis, Direct oral anticoagulants, Systematic review
Como citar
Jornal Vascular Brasileiro, v. 17, n. 4, p. 310-317, 2018.